We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co.
News

Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co.

Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co.
News

Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem Cell Sciences plc,( SCS) has licensed the use of their mouse neural stem cell technology to Merck & Co. Inc. for research use. Financial terms were not disclosed, but include a signing fee and milestone payments.

SCS believes NS cells have potential broad research applications. This includes their use in target identification/validation studies, as well as in small molecule library screening applications.

The cells and technology will be supplied by SCS from its newly opened facility in Cambridge, UK, where the Group offers a range of services to the bio-pharmaceutical industry through its SC Services business unit. With its automated cell culture equipment, SC Services provides the capability for the routine growth of stem cells including NS cells in the numbers required for high content drug screens and assays.

Furthermore, SC Services offers conversion of serum based cell lines to serum free systems, specialist genetic engineering and contract cell production.

In commenting on the agreement, David Dodd, Chairman of SCS, said: "We're very pleased to see our mouse neural stem cells being licensed by Merck and others throughout the pharmaceutical industry. Our strategy includes working with key partners to expand the widespread use of stem cells in drug discovery."

Advertisement